Retraction Note to: Aplysin enhances temozolomide sensitivity in glioma cells by increasing miR-181 level

Anjing Gong¹ · Na Ge² · Weicheng Yao¹ · Luxiang Lu¹ · Hui Liang²

Published online: 26 October 2020
© Springer-Verlag GmbH Germany, part of Springer Nature 2020

Retraction Note to:
Cancer Chemother Pharmacol (2014) 74:531–538
<https://doi.org/10.1007/s00280-014-2534-5>

The authors have retracted this article [1]. After recent further analysis of the data presented in Figures 4 and 6, it was determined that these data do not support the study conclusion that aplysin enhances glioma cell sensitivity to temozolomide.

All authors agree with this retraction.

Reference

1. Gong A, Ge N, Yao W et al (2014) Aplysin enhances temozolomide sensitivity in glioma cells by increasing miR-181 level. *Cancer Chemother Pharmacol* 74:531–538

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The original article can be found online at <https://doi.org/10.1007/s00280-014-2534-5>.

✉ Hui Liang
ajgqdfy@163.com

¹ Department of Neurosurgery, The Affiliated Hospital of Qingdao University, Qingdao 266003, China

² The Institute of Human Nutrition, Medical College of Qingdao University, 38 Dengzhou Road, Qingdao 266021, China